Clinical Trial 24408

• Overview

  Study Title:

  A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced soft tissue sarcoma

  Summary:

  The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated soft tissue sarcoma. The length of the study for each participant may be up to 5 calendar years after receiving lifileucel. After Screening, each participant will have surgery to remove some tumor pieces that will be used to make the lifileucel, followed by a baseline visit prior to study treatment. Participants will then receive the lifileucel treatment regimen. This includes 2 drugs (cyclophosphamide and fludarabine) for up to 5 days to decrease lymphocytes in the body, the lifileucel infusion (1 day), and up to 4 days of aldesleukin to boost the activity of the lifileucel. Study visits will be every 6 weeks for 6 months, then every 3 months until 5 calendar years after the lifileucel infusion.

  Objective:

  Primary Objectives: To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the IRC Secondary Objectives: To evaluate the efficacy of lifileucel as measured by CR rate, DOR, DCR, and PFS per RECIST v1.1 as assessed by the IRC To evaluate the efficacy of lifileucel as measured by ORR, CR rate, DOR, DCR, and PFS per RECIST v1.1 as assessed by the investigators To evaluate the efficacy of lifileucel as measured by OS To evaluate safety and tolerability of lifileucel Exploratory Objectives: To identify immune correlates of efficacy and/or safety variables To evaluate the HRQoL

• Treatments

  Therapies:

  Cell Therapy; Chemotherapy; Immunotherapy; Therapy (NOS)

  Medications:

  Aldesleukin (); Fludarabine (); Lifileucel (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide)

• Inclusion Criteria

  Key Inclusion Criteria:
  • Participant must be ≥ 16 years of age at the time of signing the informed consent and assent.
  • Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
  • Participant must have a confirmed diagnosis of histologically confirmed unresectable or metastatic UPS (Cohort 1) or DDLPS (Cohort 2), with or without a well-differentiated component, who have received ≥ 1 and a maximum of 3 prior systemic therapies, including ≥ 1 anthracycline-based regimen.
  • Participant has demonstrated progressive disease on or after the last line of therapy.
  • Participant is assessed as having at least one resectable lesion (or aggregate lesions) with an estimated minimum diameter of 1.5 cm (short axis) for lifileucel generation.
  • Following tumor resection for lifileucel generation, the participant will have at least one measurable lesion, as defined by RECIST v1.1 at Baseline.
  • Participant is expected to achieve washout from investigational or anticancer therapy(ies). If the participant has preplanned surgical procedure(s), the procedure will take place at least 14 days (for major operative procedures) prior to the tumor resection. Wound healing will have occurred, and all complications will have resolved at the time of tumor resection.
  • Participant has recovered from all prior anticancer treatment-related AEs to Grade ≤ 1(per NCI-CTCAE), except for peripheral neuropathy, alopecia, or vitiligo.
  • Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
  • Participants must have adequate organ function.
  • Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.

• Exclusion Criteria

  Key Exclusion Criteria:
  • Participant has symptomatic untreated brain metastases.
  • The participant has an ECOG performance status of ≥ 2, a need for urgent therapy due to rapidly progressive disease or tumor mass effect, or an estimated life expectancy of> Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation.
  • Participant has any form of primary immunodeficiency (eg, severe combined immunodeficiency disease [SCID] or AIDS).
  • Participant has a history of hypersensitivity to any component of the study intervention.
  • Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or have been curatively treated > 1 year ago, and in the judgment of the investigator does not pose a significant risk of recurrence.
  • Other protocol defined inclusion/exclusion criteria could apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.